Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-04-03
2007-04-03
Lankford, Jr., Leon B. (Department: 1651)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093400, C424S094200, C424S094400, C424S094600, C435S174000, C435S175000
Reexamination Certificate
active
10731877
ABSTRACT:
The present invention generally relates to the treatment of uremic toxins in vivo using uremic toxin-treating enzymes, and/or cells capable of producing uremic toxin-treating enzymes or otherwise reacting with uremic toxins. Non-limiting examples of cases where the treatment of uremic toxins is desired include renal disease or dysfunction, gout, subjects receiving chemotherapy, or the like. In one aspect, the treatment includes an oral delivery composition able to reduce the blood concentration of one or more non-protein nitrogen compounds in vivo. The composition, in some cases, may comprise one, two, or more uremic toxin-treating enzymes, such as urease, uricase or creatininase. The oral delivery composition may be able to deliver the uremic toxin-treating enzymes, substantially undigested, to the intestines, where the enzymes can interact with uremic toxins transported to the intestines from the bloodstream. In another aspect, the treatment includes an oral delivery composition comprising a cell able to reduce the concentration of one or more uremic toxins in vivo. In some cases, the cell may be designed to overexpress one, two, or more uremic toxin-treating enzymes, such as urease, uricase or creatininase, for example, by transfecting the cell with a corresponding gene. In some embodiments, a species able to react with or otherwise sequester by-products of the uremic toxin-treating enzyme reactions may be included with the oral delivery composition. For example, if the by-product is ammonium, the species may be a sorbent able to adsorb ammonium, an enzyme able to react with the ammonium, or the like.
REFERENCES:
patent: 3954678 (1976-05-01), Marquisee
patent: 4022833 (1977-05-01), Diana et al.
patent: 4022883 (1977-05-01), Setala
patent: 4240376 (1980-12-01), Kominami et al.
patent: 4857555 (1989-08-01), Smith et al.
patent: 5627065 (1997-05-01), Yamamoto et al.
patent: 5728562 (1998-03-01), Shigyo et al.
patent: 6126938 (2000-10-01), Guy et al.
patent: 6217859 (2001-04-01), Chang et al.
patent: 2001/0051150 (2001-12-01), Ranganathan et al.
patent: WO 97/26903 (1997-07-01), None
patent: WO 02/069922 (2002-09-01), None
Prakash et al, “In vitro and in vivo uric acid lowering by artificial cells containing microencapsulated genetically engineeredE. coliDH5 cells,” The International Journal of Artificial Organs, 2000, vol. 23, No. 7, pp. 429-435.
The On-line Medical Dictionary “Creatininase” Mar. 5, 2000, accessed Feb. 28, 2005 http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=creatininase.
The On-line Medical Dictionary “Creatinine” Sep. 27, 1997, accessed Feb. 28, 2005 http://cancerweb.nci.ac.uk.cgi-bin/omd?creatinine.
The On-line Medical Dictionary “Uricase” Dec. 12, 1998, accessed Feb. 28, 2005 http://cancerweb.nci.ac.uk/cgi-bin/omd?uricase.
The On-line Medical Dictionary “Allantoin” Oct. 9, 1997, accessed Feb. 28, 2005 http://cancerweb.nci.ac.uk/cgi-bin/omd?allantoin.
The On-line Medical Dictionary “Urease” Oct. 9, 1997, accessed Feb. 28, 2005 http://cancerweb.nci.ac.uk/cgi-bin/omd?urease.
Merriam-Webster Online Dictionary “Enteric” accessed Feb. 28, 2005 http://www.m-w.com/cgi-bin/dictionary?book=Dictionary&va=enteric.
Sparks et al, Trans. Am. Soc. Artif. Org., 1972, vol. 18, pp. 458-464, 484.
IUBMB Enzyme Nomenclature “EC 3.5.2 10” retrieved from http://www.chem.qmul.ac.uk/iubmb/enzyme/EC3/5/2/10.htm on Jul. 6, 2006.
Davankov, Vadim, et al., “Polymeric adsorbent for removing toxic proteins from blood of patients with kidney failure,”Journal of Chromatography B, 739 (2000) 73-80.
Friedman, Eli A., M.D., “Can Bacteria Be Trained to Do the Kidney's Work?” http://www.thedoctorwillseeyounow.com/articles/emerging—treatments/kidneyre...2003-10-15, pp. 1-4.
Gardner, D. L., et al., “An Orally Administered Microcapsule System for Treating Chronic Renal Failure Patients,”Applied Biochemistry and Biotechnology, vol. 10, 1984, pp. 27-40, Received Nov. 1983; Accepted Dec. 1983.
Malchesky, Paul S., M.S., et al., “Biological reactors as artificial organs: Concept and preliminary in vitro study,”Cleveland Clinic Quarterly, 42: 267-271, vol. 42, No. 3, Fall 1975.
O'Loughlin, J. A., et al., “Microencapsulated Enzymes for Enteral Removal of Uremic Toxins,”Blood Purification, 2003; 21: 350-367, 21st Annual Meeting of the International Society of Blood Purification (ISBP), Uncasville, CT, Sep. 2003, (Abstract).
O'Loughlin, J. A., et al., “Degradation of Uremic Toxins With Free and Encapsulated Enzymes,” Presented at the meeting of the American Society of Artificial and Internal organs (ASAIO), Washington, DC, Jun. 2004, (Absract).
O'Loughlin, J. A., et al., “Kinetics of Urea Degradation By Genetically ModifiedE. coli,” Presented at the meeting of the American Society of Artificial and Internal organs (ASAIO), New York, NY, Jun. 2002, p. 194, (Abstract).
O'Loughlin, J. A., et al., “Encapsulation of Mammalian And Bacterial Cells,” Presented at the meeting for the Materials Research Society (MRS), Boston, MA, Nov. 2001, p. 640, (Abstract).
O'Loughlin, J. A., et al., “Release Of Albumin From Alginate Microspheres,” Presented at the meeting for the Proceedings of the Controlled Release Society, San Diego, CA, Jun. 2001, #6042, (Abstract).
O'Loughlin, J. A., et al., “Degradation of Uremic Toxins with Free and Encapsulated Enzymes,” Presented at the meeting of the Controlled Release Society, Glasgow, Scotland, Jun. 2003, (Abstract).
Prakash, S., et al., “Microencapsulated genetically engineered liveE. coliDH5 cells administered orally to maintain normal plasma urea level in uremic rats,”Nature medicine, vol. 2, No. 8, Aug. 1996, pp. 883-887.
Ronco, Claudio, et al., First Clinical Experience with an Adjunctive Hemoperfusion Device Designed Specifically to Remove B2-in Microglobulin in Hemodialysis,Blood Purification, 2001; 19: 260-263.
Setala, K., et al., “Bacterial enzymes in uremia management,”Kidney International, vol. 13, Suppl. 8 (1978), pp. S-194-S-202.
Setala, K., et al., “Treating uremia with soil bacterial enzymes: further developments*,”Clinical Nephrology, Vo. 11, No. 3—1979 (pp. 156-166).
Winchester, James F., et al., “Sorbent Augmented Dialysis: Minor Addition or Major Advance in Therapy?”Blood Purification, 2001; 19: 255-259.
Wolfe, E. A., et al., “Orally ingested microencapsulated urease and an adsorbent, zirconium phosphate, to remove urea in kidney failure,”The International Journal Of Artificial Organs, vol. 10, No. 4, 1987, pp. 269-274.
Nishida, Y., et al., “Hypo Uricemic Effect After Oral Administration In Chickens Of Poly Ethylene Glycol Modified Uricase Entrapped In Liposomes,”Journal of Pharmacy and Pharmacology, vol. 36, No. 5, 1984, pp. 354-355.
Sprandel, U., “Erythrocytes as carrier for therapeutic enzymes—an approach towards enzyme therapy of inborn errors of metabolism,”Bibliotheca haematologica, 1985, No. 51, pp. 7-14.
Search report mailed Apr. 22, 2005 from International Application No. PCT/US2004/040580, filed Dec. 3, 2004.
Bruder Jan Markus
Lysaght Michael J.
O'Loughlin Jill A.
Brown University
Ford Allison M.
Lankford , Jr. Leon B.
Wolf Greenfield & Sacks P.C.
LandOfFree
Systems and methods related to degradation of uremic toxins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Systems and methods related to degradation of uremic toxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Systems and methods related to degradation of uremic toxins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3746329